Group 1 - China Coal Australia (03668.HK) maintains a "Buy" rating with a target price of HKD 38, benefiting from rising natural gas prices due to Middle East geopolitical conflicts, which may drive coal prices up, enhancing profitability by 5% for every 1% increase in coal prices [1] - Aubo Holdings (00880.HK) holds a "Neutral" rating with a target price of HKD 2.20, facing short-term market share pressure and a 3% decline in EBITDA margin due to the closure of satellite entertainment venues, but is working on property upgrades to attract customers [1] - Neway Group (01686.HK) is upgraded to a "Buy" rating with a target price of HKD 8.58, as its MEGA IDC phase one has a 91% occupancy rate, and demand for AI reasoning and high-density deployment is significantly increasing [1] Group 2 - JD Group (09618.HK) receives a "Strong Buy" rating, with Q4 retail operating profit down only 2.5% year-on-year, better than expected, and a recovery in food delivery losses, alongside double-digit growth in daily necessities and 3P advertising revenue [2] - JD Logistics (02618.HK) maintains a "Buy" rating, with Q4 non-IFRS net profit up 5.7%, driven by significant internal revenue growth of 68% from instant delivery, and the privatization of Debon is expected to accelerate network integration and profitability recovery [2] Group 3 - China Tobacco Hong Kong (06055.HK) holds a "Buy" rating, with a projected 14.8% year-on-year growth in net profit for 2025, and a 6.2 percentage point increase in H2 cigarette export gross margin to 21.4%, attributed to channel expansion and product optimization [3] Group 4 - Bilibili-W (09626.HK) maintains a "Buy" rating, with Q4 DAU up 10% to 113 million, and advertising revenue increasing by 27%, driven by improved ad efficiency and AIGC tool applications, achieving annual profitability for the first time [4] Group 5 - Bosideng (03998.HK) holds a "Buy" rating, achieving mid-single-digit revenue growth despite a warm winter, with brand strength reinforced through designer series and successful international expansion [5] Group 6 - Swire Properties (01972.HK) maintains a "Buy" rating, with 67% completion of its HKD 100 billion investment plan, and a projected 9% CAGR for mainland IP rights area by 2032, showcasing strong financial health and stable dividend growth [6] Group 7 - Shangmei Co. (02145.HK) holds a "Buy" rating, with projected revenue growth of 34.0%-35.4% and net profit growth of 41.9%-44.4% for 2025, driven by strong sales of popular product lines and healthy channel structure [7]

Group 1 - Invea Therapeutics, a clinical-stage biotech company developing oral small molecule drugs for inflammatory diseases, withdrew its initial public offering (IPO) plan due to market conditions [1] - The company had previously filed a prospectus to issue 3.2 million shares at a price range of $10 to $12 per share, aiming to raise $35 million [1] - Founded in 2021 and headquartered in Guilford, Connecticut, Invea Therapeutics planned to list on NASDAQ under the ticker symbol INAI [1] Group 2 - ThinkEquity was set to be the exclusive book-running manager for the IPO transaction [1]

Group 1 - The core viewpoint of the news highlights the recent downturn in the Asia-Pacific market, particularly in the Hong Kong pharmaceutical sector, with the Hong Kong Stock Connect Innovation Drug ETF (159570) experiencing a nearly 2% decline, despite a significant net subscription of 210 million yuan and a total scale exceeding 23.1 billion yuan [1][3] - The high-level meeting has officially categorized innovative drugs as an "emerging pillar industry," emphasizing the acceleration of commercial health insurance development and the promotion of high-quality development in innovative drugs [3] - The approval of Hansoh Pharmaceutical's application for the listing of Amivantamab tablets marks a significant milestone, as it is the first domestically developed third-generation EGFR-TKI in China, with five approved indications since its initial approval in March 2020 [3] Group 2 - In business development news, China Biologic Products announced an exclusive licensing agreement with Sanofi for Rovafatinib, a novel oral small molecule JAK/ROCK inhibitor, with potential payments totaling up to 1.53 billion USD, including an upfront payment of 135 million USD [4] - The Hong Kong Stock Connect Innovation Drug ETF (159570) saw most of its index's popular stocks decline, with notable drops including 5% for 3SBio and over 4% for CanSino Biologics, while Hansoh Pharmaceutical saw a slight increase due to new drug news [4] - The innovative drug sector is experiencing short-term volatility, but the long-term growth potential remains intact, with a focus on the globalization of Chinese pharmaceutical companies and the advancement of innovative technologies [6][9] Group 3 - The focus of the market has shifted from the ability to enter overseas markets to the progress of products in overseas clinical deployments, with key data readouts and milestone achievements becoming critical for future evaluations [7] - Chinese companies are making breakthroughs in frontier technologies such as small nucleic acids and cell therapies, positioning themselves as core assets in global transactions [8] - Leading innovative drug companies are entering a positive cycle of product commercialization and reinvestment in research and development, with expectations for significant performance improvements in the upcoming earnings period [9]

Core Viewpoint - Bilibili's revenue in Q4 of last year grew by 8% year-on-year, with advertising revenue increasing by 27%, surpassing expectations by 3% [1] Financial Performance - Value-added services revenue increased by 6% year-on-year, meeting expectations, while the average monthly paying users rose by 19%, reaching a historical high [1] - Non-GAAP operating profit and net profit reached 839 million and 878 million yuan, respectively, representing significant increases of 81% and 94%, exceeding expectations by 2% and 10% [1] Investment Plans - Bilibili plans to invest an additional 500 million to 1 billion yuan in AI, including capital expenditures for AI computing power and technology, as well as operational investments in R&D and talent acquisition [1] - These investments are expected to enhance efficiency, reduce costs, increase advertising revenue, and strengthen the company's competitive advantage in content communities [1] Game Development - Two new games, "Three Kingdoms: Hundred Generals Card" and "Shining! Lume," are expected to launch in Q2 of this year, which may improve the outlook for the gaming business [1] Stock Rating - The target price for Bilibili's US stock is maintained at $30, with a "Buy" rating, and the company is expected to achieve a 9% year-on-year revenue growth and a 37% increase in Non-GAAP net profit this year [1]

Core Viewpoint - Citigroup's report highlights that BYD's advanced battery and charging capabilities require systematic technological advancements that are difficult for competitors to replicate, potentially providing BYD with at least a six-month market lead [1] Group 1: Technological Advancements - The report emphasizes that the development of ultra-fast charging facilities can enhance BYD's brand competitiveness, creating a spillover effect that justifies the investment [1] - Citigroup maintains that significant technological progress in battery and charging systems is essential for BYD's competitive edge [1] Group 2: Sales Forecast - Citigroup maintains its sales forecast for BYD at 5.39 million units by 2026, with overseas sales projected between 1.5 million to 1.6 million units, and domestic sales expected to be around 3.7 million to 3.8 million units [1] - The focus on high-end brands is anticipated for BYD this year, supported by the advanced technology of ultra-fast charging [1] Group 3: Investment Rating - Citigroup retains a "Buy" rating on BYD's H-shares, setting a target price of HKD 174 [1]

Core Insights - NVIDIA's CEO Jensen Huang stated that the memory supply shortage is beneficial for the company, allowing customers to choose the most powerful solutions available [1] - Huang mentioned that NVIDIA will utilize as much production capacity from memory manufacturers as they can provide [1] Group 1 - The memory supply shortage is seen as a positive development for NVIDIA [1] - Customers are encouraged to select high-performance solutions due to the memory constraints [1] - NVIDIA's strategy involves maximizing the use of available memory production capacity [1]

Core Viewpoint - Fosun International (00656.HK) announced plans for share buybacks by its controlling shareholder and senior management, reflecting confidence in the company's growth potential and long-term investment value, despite a recent profit warning indicating expected losses for 2025 [2] Group 1: Share Buyback Plans - The controlling shareholder, Fosun Holdings Limited, and senior management plan to increase their holdings in the company within 12 months following the announcement of the 2025 annual results [2] - The total amount for the proposed share buyback will not exceed HKD 500 million, in compliance with the Hong Kong Stock Exchange's rules regarding minimum public float [2] Group 2: Financial Outlook - Fosun International issued a profit warning, projecting a loss between RMB 21.5 billion and RMB 23.5 billion for the year 2025 [2]

Group 1 - Barclays has lowered Oracle Corporation's target price from $310 to $230 [1]

Group 1 - Hong Kong bank stocks are experiencing a decline, with Standard Chartered Group down 5.55% to HKD 168.4, Bank of China Hong Kong down 4.59% to HKD 40.34, HSBC Holdings down 4.44% to HKD 129.2, and East Asia Bank down 3.44% to HKD 13.46 [1] - The ongoing geopolitical situation in the Middle East is creating uncertainty for Asian banks' loans in the Gulf region, where Asian and Chinese banks issued over USD 15 billion in loans last year, marking a historical high [1] - JPMorgan's report indicates that geopolitical uncertainty in the Middle East is a short-term driving factor for Hong Kong bank stock prices, with Standard Chartered expected to face a notable correction due to its high exposure to the region [1] Group 2 - Standard Chartered's loans and revenue exposure in the UAE for 2025 are projected to be 2.5% and 5.6% respectively, while HSBC's exposure in the Middle East is 2.3% for loans and 3.8% for revenue [1]

Group 1 - The core point of the article is that the Chinese interbank 30-year government bond yield increased by 3 basis points due to the unexpected rise in the Consumer Price Index (CPI) in February [1]